<DOC>
	<DOCNO>NCT00464815</DOCNO>
	<brief_summary>The purpose study demonstrate , 11-17 year old subject , non-inferiority meningococcal vaccine GSK134612 compare license meningococcal vaccine Mencevax™ .</brief_summary>
	<brief_title>Non-Inferiority Meningococcal Vaccine GSK134612 Versus Mencevax™ 11-17 Year-Old Subjects</brief_title>
	<detailed_description>Multicentre study 2 treatment group . Each subject 2 blood sample take immunogenicity analyse , one prior vaccination one take 30 day later . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parents/guardians comply requirement protocol . A male female , include , 11 17 year age time vaccination . Written inform assent/consent obtain subject/ parent guardian subject . Healthy subject establish medical history clinical examination enter study . Previously complete routine childhood vaccination best subject's/the subject 's parent's/guardian 's knowledge . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution two month vaccination . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month dose vaccine . Previous vaccination meningococcal polysaccharide vaccine serogroup A , C , W135 and/or Y within last five year . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroup A , C , W135 and/or Y . Previous vaccination tetanus toxoid within last month . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History reaction allergic disease likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede dose study vaccine plan administration study period . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>meningococcal vaccine</keyword>
</DOC>